2 weeks Ago By ABMN Staff
Vivani Medical ( NASDAQ:VANI – Get Free Report ) ‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $4.00 target price on the stock.
HC Wainwright’s price objective points to a potential upside of 277.36% from the company’s previous close. Vivani Medical Trading Up 1.
0 % Vivani Medical stock opened at $1.06 on Wednesday. Vivani Medical has a 1-year low of $0.
91 and a 1-year high of $2.09. The firm’s fifty day simple moving average is $1.
08 and its 200-day simple moving average is $1.19. The company has a market capitalization of $62.
79 million, a P/E ratio of -2.36 and a beta of 2.76.
Vivani Medical ( NASDAQ:VANI – Get Free Report ) last posted its earnings results on Monday, March 31st. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.
10) by ($0.01). On average, equities research analysts predict that Vivani Medical will post -0.
41 earnings per share for the current year. Insider Buying and Selling at Vivani Medical Institutional Inflows and Outflows Institutional investors and hedge funds have recently bought and sold shares of the company. Wealthedge Investment Advisors LLC acquired a new position in shares of Vivani Medical during the 4th quarter worth about $43,000.
Jane Street Group LLC acquired a new position in shares of Vivani Medical during the fourth quarter worth approximately $66,000. Northern Trust Corp boosted its position in shares of Vivani Medical by 19.1% in the fourth quarter.
Northern Trust Corp now owns 71,915 shares of the company’s stock valued at $83,000 after acquiring an additional 11,540 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Vivani Medical by 4.6% in the third quarter.
Geode Capital Management LLC now owns 342,891 shares of the company’s stock worth $401,000 after acquiring an additional 15,008 shares during the last quarter. Institutional investors and hedge funds own 6.78% of the company’s stock.
About Vivani Medical ( Get Free Report ) Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. Featured Articles Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.
com's FREE daily email newsletter ..
